The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a significant substantial reduction in body mass and benefit metabolic ma